Development of an interpretable machine learning model to predict complete remission and first adverse event in pediatric acute myeloid leukemia using routine clinical data.
1/5 보강
[BACKGROUND] Pediatric acute myeloid leukemia (pAML) is a rapidly progressive myeloid malignancy characterized by malignant clonal expansion of hematopoietic stem and progenitor cells.
- 95% CI 0.86-0.97
APA
Huang N, Wang W, et al. (2026). Development of an interpretable machine learning model to predict complete remission and first adverse event in pediatric acute myeloid leukemia using routine clinical data.. Frontiers in oncology, 16, 1739432. https://doi.org/10.3389/fonc.2026.1739432
MLA
Huang N, et al.. "Development of an interpretable machine learning model to predict complete remission and first adverse event in pediatric acute myeloid leukemia using routine clinical data.." Frontiers in oncology, vol. 16, 2026, pp. 1739432.
PMID
42038377 ↗
Abstract 한글 요약
[BACKGROUND] Pediatric acute myeloid leukemia (pAML) is a rapidly progressive myeloid malignancy characterized by malignant clonal expansion of hematopoietic stem and progenitor cells. The prediction of complete remission (CR) and first adverse event (AE) is critical for personalizing pAML treatment; however, interpretable machine learning (ML) models that utilize only routine clinical features for this purpose are lacking.
[METHODS] A total of 206 pediatric AML patients (excluding acute promyelocytic leukemia) were randomly split into training (80%) and test (20%) sets. Seven supervised ML algorithms were constructed for predicting CR and AE, and their performance was evaluated by accuracy, specificity, F1-score, and area under the receiver operating characteristic curve (AUC). Model interpretability was assessed using feature importance, accumulated local effect (ALE) plots, and SHAP values.
[RESULTS] To identify optimal predictors of CR, three feature selection methods-random forest, stepwise regression, and joint mutual information maximization (JMIM)-were employed. Their intersection revealed seven key features: age, bone marrow blasts, peripheral blood blasts, platelet count (PLT), t (8;21), TP53 and del7/del7q. The random forest model demonstrated optimal performance, with a training AUC of 0.90 (95% CI: 0.86-0.97) and a test AUC of 0.79 (95% CI: 0.72-0.86). The similar machine learning pipeline was applied to predict the first adverse event (AE). Nine features were selected as optimal predictors through the intersection of the same three algorithms: white blood cell count (WBC), peripheral blood blasts, PLT, bone marrow blasts, hemoglobin, age, t (8;21), NPM1 and KIT. For AE prediction, the random forest algorithm also exhibited optimal performance, with a training AUC of 0.92 (95% CI: 0.85-0.97) and a test AUC of 0.78 (95% CI: 0.66-0.84). Interpretability analysis of the random forest models revealed that a higher platelet count at diagnosis was predictive of an increased probability of CR and a reduced risk of AE. In contrast, elevated WBC and peripheral blood blast percentage were associated with a higher incidence of AE.
[CONCLUSION] Our random forest model, built on routine hematological parameters, demonstrated strong potential for predicting CR and AE in pAML, thereby facilitating early risk stratification and guiding personalized treatment strategies.
[METHODS] A total of 206 pediatric AML patients (excluding acute promyelocytic leukemia) were randomly split into training (80%) and test (20%) sets. Seven supervised ML algorithms were constructed for predicting CR and AE, and their performance was evaluated by accuracy, specificity, F1-score, and area under the receiver operating characteristic curve (AUC). Model interpretability was assessed using feature importance, accumulated local effect (ALE) plots, and SHAP values.
[RESULTS] To identify optimal predictors of CR, three feature selection methods-random forest, stepwise regression, and joint mutual information maximization (JMIM)-were employed. Their intersection revealed seven key features: age, bone marrow blasts, peripheral blood blasts, platelet count (PLT), t (8;21), TP53 and del7/del7q. The random forest model demonstrated optimal performance, with a training AUC of 0.90 (95% CI: 0.86-0.97) and a test AUC of 0.79 (95% CI: 0.72-0.86). The similar machine learning pipeline was applied to predict the first adverse event (AE). Nine features were selected as optimal predictors through the intersection of the same three algorithms: white blood cell count (WBC), peripheral blood blasts, PLT, bone marrow blasts, hemoglobin, age, t (8;21), NPM1 and KIT. For AE prediction, the random forest algorithm also exhibited optimal performance, with a training AUC of 0.92 (95% CI: 0.85-0.97) and a test AUC of 0.78 (95% CI: 0.66-0.84). Interpretability analysis of the random forest models revealed that a higher platelet count at diagnosis was predictive of an increased probability of CR and a reduced risk of AE. In contrast, elevated WBC and peripheral blood blast percentage were associated with a higher incidence of AE.
[CONCLUSION] Our random forest model, built on routine hematological parameters, demonstrated strong potential for predicting CR and AE in pAML, thereby facilitating early risk stratification and guiding personalized treatment strategies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- The MDM2-IL-33 Axis Promotes Gastric Tumorigenesis via K63 Ubiquitination-Dependent ERK/JNK Activation.
- WTAP participates in the DNA damage response via an mA-FOXM1-dependent manner in hepatocellular carcinoma.
- Endothelial F3-mediated autolysosome and lipid metabolism promote resistance to anti-VEGFA therapy in metastatic colorectal cancer.
- The roles of the mtDNA-cGAS-STING axis in tumor immunity: from immune activation to immune evasion.
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children.
- Patient-Perceived Overall Side Effect Bother at and After Cancer Treatment Discontinuation: An Analysis Using Commercial Cancer Trial Data.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.
- Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer.